Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Prior treatment

• Had any immune-related side effect or allergic reaction (Grade 3 or higher) from a previous immunotherapy medicine, or any immune-related side effect greater than Grade 1 that has not resolved. This does not apply for people with hormone-related diseases who are now on stable hormone replacement therapy.

Other illness

• Have another type of cancer that is progressing or required active treatment within the past 2 years before screening.
• Have an active autoimmune disease that required systemic treatment in the past 2 years. Endocrine replacement therapy is allowed.

Lab values

• Have known, actionable changes in the EGFR or ALK genes.

• Histological or cytological confirmation of NSCLC.
  • Part A
  • Clinical Stage II-IIIB (N0, N1, N2) treated with presurgical chemoimmunotherapy, with residual tumor present at time of surgery. Patients with a pathologic complete response are not eligible.
  • Pathologic Stage II-IIIB (N0, N1, N2) NSCLC treated with initial upfront resection.
  • Part B - Clinical Stage III, unresectable NSCLC, without progression on concurrent platinum-based chemoradiotherapy.
• Must have disease with evidence of KRAS G12C mutation.
• Must have known programmed death-ligand 1 (PD-L1) expression
• Must have an ECOG performance status of 0 or 1.
• Able to swallow oral medication.
• Must have adequate laboratory parameters.
• Contraceptive use should be consistent with local regulations for those participating in clinical studies.
• Women of childbearing potential must
  • Have a negative pregnancy test.
  • Not be breastfeeding during treatment